Overview

Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis

Status:
Terminated
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether eculizumab is safe and effective in the treatment of patients with generalized myasthenia gravis despite treatment with various immunosuppressants, such as prednisone, methotrexate, Cellcept, cyclosporine, and cyclophosphamide, that are currently available.
Phase:
Phase 2
Details
Lead Sponsor:
Alexion Pharmaceuticals
Treatments:
Eculizumab